Gene · 5739
PTGIR: prostaglandin I2 receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PTGIR: prostaglandin I2 receptor. Genes, record 5739. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5739
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P43119 | Prostacyclin receptor | 386 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents52
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59423 | P43119 | Espacenet |
| JP 2025172069 A | 2025-11-20 | 443 | P43119 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 3455 | P43119 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3042 | P43119 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 11045 | P43119 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3626 | P43119 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 7487 | P43119 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3626 | P43119 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 7487 | P43119 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3042 | P43119 | Espacenet |
1 to 10 of 52
See all 52 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| EPOPROSTENOL | CHEMBL1139 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| EPOPROSTENOL SODIUM | CHEMBL962 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| ESUBERAPROST | CHEMBL3137314 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| ILOPROST | CHEMBL494 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| ILOPROST TROMETHAMINE | CHEMBL5315118 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| RALINEPAG | CHEMBL3301604 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| SELEXIPAG | CHEMBL238804 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| TREPROSTINIL | CHEMBL1237119 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| TREPROSTINIL DIOLAMINE | CHEMBL2107815 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
| TREPROSTINIL SODIUM | CHEMBL561157 | Prostanoid IP receptor agonist | AGONIST | ChEMBL |
Trials197
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07450469 | ILOPROST | ClinicalTrials.gov | ||
| NCT07356375 | SELEXIPAG | ClinicalTrials.gov | ||
| NCT07285655 | TREPROSTINIL | PHASE3 | ClinicalTrials.gov | |
| NCT07263958 | ILOPROST | ClinicalTrials.gov | ||
| NCT07177703 | TREPROSTINIL | PHASE2 | ClinicalTrials.gov | |
| NCT07037836 | TREPROSTINIL | PHASE2 | ClinicalTrials.gov | |
| NCT06969573 | TREPROSTINIL | PHASE2 | ClinicalTrials.gov | |
| NCT06753981 | EPOPROSTENOL | ClinicalTrials.gov | ||
| NCT06605326 | TREPROSTINIL | PHASE4 | ClinicalTrials.gov | |
| NCT06603285 | TREPROSTINIL | ClinicalTrials.gov |
1 to 10 of 197
See all 197 trialsNIH grants584
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PTGIR papers | Newest fiscal year |
|---|---|---|---|
| R01HL092961 | Epithelial-Mesenchymal Interactions in Fibrosis Resolution | 3 | 2025 |
| U19AI070535 | Airway Inflammation and Airway Remodeling in Severe Asthma | 3 | 2025 |
| U19AI095227 | Viral and Host Determinants of Infant and Childhood Allergy and Asthma | 3 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 2 | 2025 |
| R01HL077612 | Precision phenotyping of emphysema in the elderly: the MESA Lung Study | 2 | 2025 |
| R01HL111656 | Vascular Targeting Genomic & Genetic Strategies for Acute Chest Syndrome | 2 | 2025 |
| T32HL007284 | Basic Cardiovascular Research Training Grant | 2 | 2025 |
| T32HL007853 | Multidisciplinary Cardiovascular Research Training | 2 | 2025 |
1 to 10 of 584Source NIH's project files
See all 584 nih grantsPapers1,202
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension. | Ther Adv Respir Dis | 2026 | 42808704 | PubTator, text mining | PubMed |
| Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review. | Rev Cardiovasc Med | 2026 | 42238623 | PubTator, text mining | PubMed |
| Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children. | BMC Pediatr | 2026 | 42104335 | PubTator, text mining | PubMed |
| Prostaglandin I2 receptor activation promotes alveolar regeneration via the JUN/p53 pathway. | Am J Respir Crit Care Med | 2026 | 42085259 | PubTator, text mining | PubMed |
| Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension. | Pulm Ther | 2026 | 41952024 | PubTator, text mining | PubMed |
| Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management. | IUBMB Life | 2026 | 41885124 | PubTator, text mining | PubMed |
| PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes. | PLoS One | 2026 | 41790620 | PubTator, text mining | PubMed |
| Regulatory roles of bioactive lipids in vascular homeostasis and remodeling. | Med Rev (2021) | 2026 | 41783891 | PubTator, text mining | PubMed |
| Development of immune-derived molecular markers for coronary heart disease via multimachine learning. | iScience | 2026 | 41782820 | PubTator, text mining | PubMed |
| The Pathophysiology, Mechanism, Diagnosis, and Management of Pulmonary Arterial Hypertension: A Comprehensive Literature Review. | US Cardiol | 2026 | 41766785 | PubTator, text mining | PubMed |
1 to 10 of 1,202
See all 1,202 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5739
GET https://conductscience.org/api/genes/v1/5739/patents?page=2